SelectScience Members can achieve membership status by writing product reviews. This helps other members to better understand the Reviewer's experience and expertise.
Status: No. Reviews Published: Member 0 1-4 5-14 15+ By Invitation
Reviewers are also encouraged to publish a 'public profile' so others can benefit from a further understanding of the Reviewer's applications and expertise.
Write a review today>>
Member since: 2018
It is the best way to use and to see in the patient
Application Area: diagnostic testing for NSCLC
"One test that can expedite NSCLC treatment selection decisions. The Oncomine Dx Target Test is the first targeted NGS-based in vitro diagnostic test for NSCLC, simultaneously delivering multiple biomarker results from one sample within four days and helping inform treatment decisions. It is the best way to use and to see in the patient"
Member since: 2018
Simple reaction setup, downstream data analysis and clinical relevance.
Application Area:Clinal testing
"Simple reaction setup, downstream data analysis and clinical relevance also easy to find and assign."
In the era of personalized medicine, molecular profiling has become essential for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC). With an increasing number of genomic alterations becoming clinically relevant, sequential testing of individual mutations becomes a significant challenge for clinical laboratories. Next-generation sequencing (NGS), which can detect multiple alterations at once from a small amount of tissue, offers a solution.
One test that can expedite NSCLC treatment selection decisions
The Ion Torrent Oncomine Dx Target Test is the first targeted NGS-based in vitro diagnostic test for NSCLC, simultaneously delivering multiple biomarker results from one sample within four days and helping inform treatment decisions.
Oncomine Dx Target Test content
Currently, five NSCLC-associated biomarkers are targeted by first line treatment. Additional biomarkers have been recommended by scientific guidelines for adding potential value in the patient stratification process. The Oncomine Dx Target Test is the only available diagnostic test that delivers multiple biomarker identification at once. The test includes three biomarkers, validated for selection of relevant targeted therapies (EGFR, ROS1, or BRAF), and twenty additional genes, relevant for NSCLC pathogenesis analytically validated for variant detection from NSCLC tissue.
The power of next generation sequencing
Next-generation sequencing (NGS) can sequence hundreds to thousands of genes and detect multiple biomarkers at the same time. The sequencing takes place in a chip that contains millions of wells (flow cells) with separate sequencing reactions taking place in each well, allowing many genes to be sequenced at once and multiple variations to be detected simultaneously, unlike traditional companion diagnostic technologies such as FISH, IHC, or PCR, which only analyze one target gene at the time.
Oncomine Dx Target Test report
The Oncomine Dx Target Test Clinical Test Report is automatically generated as a PDF and incorporates relevant patient, sample, and test information required to help ensure high-performance standards, regulatory compliance, and quality control. The test results are presented in two-parts: companion diagnostic marker results with associated therapy indications and cancer driver analytical-only biomarker results in a separate section. The report is customizable and LIMS system-compatible.